Not yet recruitingPhase 2NCT06490341

GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator
He Xiaohui
Cancer Hospital, CAMS
Intervention
GP Regimen, Nimotuzumab, Sintilimab(drug)
Enrollment
20 enrolled
Eligibility
18-75 years · All sexes
Timeline
20242027

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06490341 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials